Literature DB >> 27061484

Anti Saccharomyces cerevisiae Antibodies in Patients With Anti-β2 Glycoprotein I Antibodies.

Amani Mankaï1,2, Skander Layouni3, Ibtissem Ghedira4,5.   

Abstract

BACKGROUND: In this study, cross-reactive epitopes on β2 glycoprotein I and Saccharomyces cerevisiae have been described. The objective of our study was to determine the frequency of anti S. cerevisiae antibodies (ASCA) in patients with anti-β2 glycoprotein I antibodies (aβ2GPI).
METHODS: A retrospective study was conducted in 77 patients with aβ2GPI (aβ2GPI-IgG or aβ2GPI-IgA). Eighty blood donors were used as a control group. ASCA IgG and ASCA IgA were determined by Enzyme Linked Immunosorbent Assay (ELISA).
RESULTS: Thirteen patients among 77 had ASCA. ASCA (IgA or IgG) was significantly more frequent in patients than in healthy subjects (16.9% vs. 3.7%, P = 0.01). The positivity of both ASCA IgG and ASCA IgA is higher in patients than in control group (6.5% vs. 0%, P = 0.02). The frequency of ASCA IgG was significantly higher in patients than in the control group (15.6% vs. 2.5%, P = 0.009). In females, the frequency of ASCA IgG was significantly higher in patients than in control group (17.5% vs. 3.7%, P = 0.03). The average titer of ASCA IgG was significantly higher in patients than in the control group (9.7 ± 23 U/ml vs. 2.2 ± 2.8 U/ml; P = 0.004). ASCA IgG was significantly more frequent than ASCA IgA in all patients (15.6% vs. 7.8%, P = 0.04).
CONCLUSION: The frequency of ASCA was significantly higher in patients with aβ2GPI than in the control group.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Tunisia; anti Saccharomyces cerevisiae antibodies; anti-β2 glycoprotein I antibodies

Mesh:

Substances:

Year:  2016        PMID: 27061484      PMCID: PMC6806701          DOI: 10.1002/jcla.21942

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  29 in total

1.  Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease.

Authors:  K R Reddy; J F Colombel; D Poulain; E L Krawitt
Journal:  Am J Gastroenterol       Date:  2001-01       Impact factor: 10.864

Review 2.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

3.  Anti-cardiolipin and anti-beta 2-glycoprotein I antibodies in celiac disease.

Authors:  A Mankaï; A Achour; Y Thabet; W Manoubia; W Sakly; I Ghedira
Journal:  Pathol Biol (Paris)       Date:  2011-08-11

4.  Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease.

Authors:  E Israeli; I Grotto; B Gilburd; R D Balicer; E Goldin; A Wiik; Y Shoenfeld
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

5.  Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

Authors:  E Matsuura; Y Igarashi; M Fujimoto; K Ichikawa; T Koike
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

6.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease.

Authors:  Jan G M C Damoiseaux; Bas Bouten; Annick M L W Linders; Jos Austen; Caroline Roozendaal; Maurice G V M Russel; Pierre-Philippe Forget; Jan Willem Cohen Tervaert
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

7.  Anti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetes.

Authors:  Wahiba Sakly; Amani Mankaï; Nabil Sakly; Yosra Thabet; Achouak Achour; Leila Ghedira-Besbes; Moncef Jeddi; Ibtissem Ghedira
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

8.  Cross-reactive epitopes on beta2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome.

Authors:  I Krause; M Blank; R Cervera; J Font; T Matthias; S Pfeiffer; I Wies; A Fraser; Y Shoenfeld
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

9.  Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease.

Authors:  R M van Elburg; J J Uil; C J Mulder; H S Heymans
Journal:  Gut       Date:  1993-03       Impact factor: 23.059

10.  Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis.

Authors:  Lucrezia Riente; Daniele Chimenti; Federico Pratesi; Andrea Delle Sedie; Simona Tommasi; Cristina Tommasi; Stefano Bombardieri; Paola Migliorini
Journal:  J Rheumatol       Date:  2004-05       Impact factor: 4.666

View more
  3 in total

Review 1.  The role of mycobiota-genotype association in inflammatory bowel diseases: a narrative review.

Authors:  Elaheh Mahmoudi; Sayed-Hamidreza Mozhgani; Niusha Sharifinejad
Journal:  Gut Pathog       Date:  2021-05-08       Impact factor: 4.181

Review 2.  Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation.

Authors:  Anush Martirosyan; Rustam Aminov; Gayane Manukyan
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

3.  IgA is the predominant isotype of anti-β2 glycoprotein I antibodies in rheumatoid arthritis.

Authors:  Sarra Melayah; Maha Changuel; Amani Mankaï; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2020-01-22       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.